The global atopic dermatitis clinical trials market size was estimated to be USD 2.34 billion in 2023 and is expected to reach at USD 7.50 billion by 2034 with a CAGR of 11.17% during the forecast period 2024-2034. Increase in technological advancements, a rise in the occurrence of atopic dermatitis, heightened financial support & investments from major market players, an upswing in partnerships between pharmaceutical & dermatological companies, an expedited process of product development, an increasing need for efficacious treatments, a surge in research and development focusing on innovative drugs, a growing trend of mergers & acquisitions among pharmaceutical firms & Contract Research Organizations (CROs), swift approval pathways for atopic dermatitis therapeutics, and an expanding pipeline of therapeutic options for addressing atopic dermatitis are some of the key factors boosting the market growth.
An expanding pipeline of therapeutic options for addressing atopic dermatitis is predicted to boost the market growth during the forecast period. There is a strong pipeline of therapeutic options currently in development to address the condition. For instance, in June 2023, Sanofi has announced encouraging top-line results from Phase 2b studies of Amlitelimab in treating atopic dermatitis. These findings support amlitelimab's potential as a novel investigational anti-OX40-ligand monoclonal antibody, positioning it as a leading candidate for the first-in-class treatment of atopic dermatitis.
By phase, Phase II was the highest revenue-grossing segment in the global atopic dermatitis clinical trials market in 2023 owing to the growing quantity of drugs is undergoing Phase II trials, accompanied by an increased investment in the clinical development of these pharmaceuticals. For instance, in October 2023, Triventi Bio has successfully raised $92 million in Series A funding to advance its primary antibody program, TRIV-509, into clinical development. Additionally, Phase III is predicted to grow at the fastest CAGR during the forecast period owing to the rising quantity of pipeline drugs for atopic dermatitis progressing into the Phase III stage of development, increasingly forming partnerships to broaden their clinical drug pipelines, scientific advancements are on the upswing, growing demand for improved treatments, and collaborative initiatives are being undertaken to tackle the challenges associated with addressing this widespread skin condition.
By molecule type, large molecules was the highest revenue-grossing segment in the global atopic dermatitis clinical trials market in 2023 owing to a growing need for biologics, an uptick in the occurrence of atopic dermatitis and skin eczema, and an increasing pipeline of products categorized as large molecules. Additionally, small molecules is predicted to grow at the fastest CAGR during the forecast period owing to an elevated request for the topical administration of drugs among the patient population, accompanied by increased investments from various pharmaceutical companies. Small molecule drugs show promise in effectively addressing atopic dermatitis, given their availability in diverse dosage forms. For instance, in December 2022, Arcutis Biotherapeutics, Inc. has disclosed favorable top-line outcomes from the INTEGUMENT-2 pivotal Phase 3 trial of roflumilast cream 0.15%. This cream, a non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, is administered once daily to adults and children aged 6 years and older who have mild to moderate atopic dermatitis (AD).
By study design, interventional trials was the highest revenue-grossing segment in the global atopic dermatitis clinical trials market in 2023 owing to the increase in the adoption of interventional study designs is observed in clinical trials. Additionally, observational is predicted to grow at the fastest CAGR during the forecast period owing to the growing market demand for products addressing atopic dermatitis and eczema, driven by an increasing need for effective therapeutics. For instance, in March 2023, LEO Pharma has presented encouraging results from the DELTA 1 pivotal Phase 3 clinical trial evaluating Delgocitinib cream. This investigational topical pan-Janus kinase (JAK) inhibitor shows promise for potential application in the treatment of moderate to severe chronic hand eczema (CHE) in adults.
North America region is anticipated for the highest revenue share during the forecast period owing to the increase in the number of individuals impacted by atopic dermatitis, supported by a strong research infrastructure that includes well-established clinical trial sites, research institutions, & academic medical centers, and an uptick in clinical trial activities. For instance, in May 2023, Sciences has reported favorable results from ADORING 1, the second Phase 3 trial assessing the effectiveness and safety of VTAMA (tapinarof) cream, 1%, in the treatment of moderate to severe atopic dermatitis in both adults and pediatric subjects starting from 2 years old. The trial was conducted in a double-blind, randomized manner. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rise in the demand for clinical trial services, driven by the cost-effectiveness provided by Contract Research Organizations (CROs), streamlined recruitment processes for clinical trials, well-established clinical infrastructure, the presence of skilled medical professionals, increase in government initiatives to encourage atopic dermatitis clinical trials, the acceptance of high-quality clinical outsourcing services, and an increased approval rate for novel treatments. For instance, in January 2022, Pfizer has received approval from the U.S. Food and Drug Administration (FDA) for CIBINQO (abrocitinib) to treat adults with moderate-to-severe atopic dermatitis.
An expanding pipeline of therapeutic options for addressing atopic dermatitis is predicted to boost the market growth during the forecast period. There is a strong pipeline of therapeutic options currently in development to address the condition. For instance, in June 2023, Sanofi has announced encouraging top-line results from Phase 2b studies of Amlitelimab in treating atopic dermatitis. These findings support amlitelimab's potential as a novel investigational anti-OX40-ligand monoclonal antibody, positioning it as a leading candidate for the first-in-class treatment of atopic dermatitis.
By phase, Phase II was the highest revenue-grossing segment in the global atopic dermatitis clinical trials market in 2023 owing to the growing quantity of drugs is undergoing Phase II trials, accompanied by an increased investment in the clinical development of these pharmaceuticals. For instance, in October 2023, Triventi Bio has successfully raised $92 million in Series A funding to advance its primary antibody program, TRIV-509, into clinical development. Additionally, Phase III is predicted to grow at the fastest CAGR during the forecast period owing to the rising quantity of pipeline drugs for atopic dermatitis progressing into the Phase III stage of development, increasingly forming partnerships to broaden their clinical drug pipelines, scientific advancements are on the upswing, growing demand for improved treatments, and collaborative initiatives are being undertaken to tackle the challenges associated with addressing this widespread skin condition.
By molecule type, large molecules was the highest revenue-grossing segment in the global atopic dermatitis clinical trials market in 2023 owing to a growing need for biologics, an uptick in the occurrence of atopic dermatitis and skin eczema, and an increasing pipeline of products categorized as large molecules. Additionally, small molecules is predicted to grow at the fastest CAGR during the forecast period owing to an elevated request for the topical administration of drugs among the patient population, accompanied by increased investments from various pharmaceutical companies. Small molecule drugs show promise in effectively addressing atopic dermatitis, given their availability in diverse dosage forms. For instance, in December 2022, Arcutis Biotherapeutics, Inc. has disclosed favorable top-line outcomes from the INTEGUMENT-2 pivotal Phase 3 trial of roflumilast cream 0.15%. This cream, a non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, is administered once daily to adults and children aged 6 years and older who have mild to moderate atopic dermatitis (AD).
By study design, interventional trials was the highest revenue-grossing segment in the global atopic dermatitis clinical trials market in 2023 owing to the increase in the adoption of interventional study designs is observed in clinical trials. Additionally, observational is predicted to grow at the fastest CAGR during the forecast period owing to the growing market demand for products addressing atopic dermatitis and eczema, driven by an increasing need for effective therapeutics. For instance, in March 2023, LEO Pharma has presented encouraging results from the DELTA 1 pivotal Phase 3 clinical trial evaluating Delgocitinib cream. This investigational topical pan-Janus kinase (JAK) inhibitor shows promise for potential application in the treatment of moderate to severe chronic hand eczema (CHE) in adults.
North America region is anticipated for the highest revenue share during the forecast period owing to the increase in the number of individuals impacted by atopic dermatitis, supported by a strong research infrastructure that includes well-established clinical trial sites, research institutions, & academic medical centers, and an uptick in clinical trial activities. For instance, in May 2023, Sciences has reported favorable results from ADORING 1, the second Phase 3 trial assessing the effectiveness and safety of VTAMA (tapinarof) cream, 1%, in the treatment of moderate to severe atopic dermatitis in both adults and pediatric subjects starting from 2 years old. The trial was conducted in a double-blind, randomized manner. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rise in the demand for clinical trial services, driven by the cost-effectiveness provided by Contract Research Organizations (CROs), streamlined recruitment processes for clinical trials, well-established clinical infrastructure, the presence of skilled medical professionals, increase in government initiatives to encourage atopic dermatitis clinical trials, the acceptance of high-quality clinical outsourcing services, and an increased approval rate for novel treatments. For instance, in January 2022, Pfizer has received approval from the U.S. Food and Drug Administration (FDA) for CIBINQO (abrocitinib) to treat adults with moderate-to-severe atopic dermatitis.
Segmentation: Atopic Dermatitis Clinical Trials Market Report 2023 - 2034
Atopic Dermatitis Clinical Trials Market Analysis & Forecast by Phase 2023 - 2034 (Revenue USD Bn)
- Phase IV
- Phase III
- Phase II
- Phase I
Atopic Dermatitis Clinical Trials Market Analysis & Forecast by Molecule Type 2023 - 2034 (Revenue USD Bn)
- Large Molecules
- Small Molecules
Atopic Dermatitis Clinical Trials Market Analysis & Forecast by Study Design 2023 - 2034 (Revenue USD Bn)
- Observational
- Interventional
Atopic Dermatitis Clinical Trials Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Atopic Dermatitis Clinical Trials Market: Phase Estimates & Trend Analysis
8. Atopic Dermatitis Clinical Trials Market: Molecule Type Estimates & Trend Analysis
9. Atopic Dermatitis Clinical Trials Market: Study Design Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Atopic Dermatitis Clinical Trials Market
12. Europe Global Atopic Dermatitis Clinical Trials Market
13. Asia Pacific Global Atopic Dermatitis Clinical Trials Market
14. Latin America Global Atopic Dermatitis Clinical Trials Market
15. MEA Global Atopic Dermatitis Clinical Trials Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Oncodesign services
- Imavita
- Redoxis
- Novotech
- BIOCYTOGEN
- Syneos Health
- QIMA LTD
- Charles River Laboratories
- REPROCELL Inc.
- Hooke Laboratories LLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.34 Billion |
| Forecasted Market Value ( USD | $ 7.5 Billion |
| Compound Annual Growth Rate | 11.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
